Cargando…

Stevens-Johnson Syndrome Induced by Vandetanib

Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jimi, Oh, Chee Won, Kim, Chi Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/
https://www.ncbi.nlm.nih.gov/pubmed/22346274
http://dx.doi.org/10.5021/ad.2011.23.S3.S343
_version_ 1782223406354137088
author Yoon, Jimi
Oh, Chee Won
Kim, Chi Yeon
author_facet Yoon, Jimi
Oh, Chee Won
Kim, Chi Yeon
author_sort Yoon, Jimi
collection PubMed
description Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
format Online
Article
Text
id pubmed-3276793
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Korean Dermatological Association; The Korean Society for Investigative Dermatology
record_format MEDLINE/PubMed
spelling pubmed-32767932012-02-16 Stevens-Johnson Syndrome Induced by Vandetanib Yoon, Jimi Oh, Chee Won Kim, Chi Yeon Ann Dermatol Case Report Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011-12 2011-12-27 /pmc/articles/PMC3276793/ /pubmed/22346274 http://dx.doi.org/10.5021/ad.2011.23.S3.S343 Text en Copyright © 2011 Korean Dermatological Association; The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Yoon, Jimi
Oh, Chee Won
Kim, Chi Yeon
Stevens-Johnson Syndrome Induced by Vandetanib
title Stevens-Johnson Syndrome Induced by Vandetanib
title_full Stevens-Johnson Syndrome Induced by Vandetanib
title_fullStr Stevens-Johnson Syndrome Induced by Vandetanib
title_full_unstemmed Stevens-Johnson Syndrome Induced by Vandetanib
title_short Stevens-Johnson Syndrome Induced by Vandetanib
title_sort stevens-johnson syndrome induced by vandetanib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/
https://www.ncbi.nlm.nih.gov/pubmed/22346274
http://dx.doi.org/10.5021/ad.2011.23.S3.S343
work_keys_str_mv AT yoonjimi stevensjohnsonsyndromeinducedbyvandetanib
AT ohcheewon stevensjohnsonsyndromeinducedbyvandetanib
AT kimchiyeon stevensjohnsonsyndromeinducedbyvandetanib